Advanced search
Publication Cover
Expert Review of Cardiovascular Therapy Volume 10, 2012 - Issue 12
Submit an article Journal homepage
119
Views
8
CrossRef citations to date
0
Altmetric
Theme: Thrombosis - Perspective

Antiplatelets in acute coronary syndrome: personal perspectives

Rossella Marcucci Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy. [email protected]
,
Caterina Cenci Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy
,
Gabriele Cioni Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy
,
Alessandra Lombardi Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy
,
Betti Giusti Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy
&
Gian Franco Gensini Department of Medical and Surgical Critical Care, University of Florence, Florence, Italy
Pages 1487-1496 | Published online: 10 Jan 2014

References

  • Sofi F, Marcucci R, Gori AM, Giusti B, Abbate R, Gensini GF. Clopidogrel non-responsiveness and risk of cardiovascular morbidity. an updated meta-analysis. Thromb. Haemost. 2, 103–110 (2010).
  • Bonello L, Tantry US, Marcucci R et al.; Working Group on High On-Treatment Platelet Reactivity. Consensus and future directions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J. Am. Coll. Cardiol. 56(12), 919–933 (2010).
  • Paniccia R, Antonucci E, Maggini N et al. Comparison of methods for monitoring residual platelet reactivity after clopidogrel by point-of-care tests on whole blood in high-risk patients. Thromb. Haemost. 104(2), 287–292 (2010).
  • Marcucci R, Gori AM, Paniccia R et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up. Circulation 119(2), 237–242 (2009).
  • Buonamici P, Marcucci R, Migliorini A et al. Impact of platelet reactivity after clopidogrel administration on drug-eluting stent thrombosis. J. Am. Coll. Cardiol. 49(24), 2312–2317 (2007).
  • Migliorini A, Valenti R, Marcucci R et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 120(22), 2214–2221 (2009).
  • Sibbing D, Braun S, Jawansky S et al. Assessment of ADP-induced platelet aggregation with light transmission aggregometry and multiple electrode platelet aggregometry before and after clopidogrel treatment. Thromb. Haemost. 99(1), 121–126 (2008).
  • Price MJ, Endemann S, Gollapudi RR et al. Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. Eur. Heart J. 29(8), 992–1000 (2008).
  • Gurbel PA, Mahla E, Antonino MJ, Tantry US. Response variability and the role of platelet function testing. J. Invasive Cardiol. 21(4), 172–178 (2009).
  • Aradi D, Komócsi A, Vorobcsuk A et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. Am. Heart J. 160(3), 543–551 (2010).
  • Parodi G, Marcucci R, Valenti R et al. High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. JAMA 306(11), 1215–1223 (2011).
  • Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med. 345(7), 494–502 (2001).
  • Yousuf O, Bhatt DL. The evolution of antiplatelet therapy in cardiovascular disease. Nat. Rev. Cardiol. 8(10), 547–559 (2011).
  • Patrono C, Baigent C, Hirsh J, Roth G; American College of Chest Physicians. Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133(Suppl. 6), 199S–233S (2008).
  • Gurbel PA, Bliden KP, Hiatt BL, O’Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 107(23), 2908–2913 (2003).
  • Gurbel PA, Bliden KP, Hayes KM, Yoho JA, Herzog WR, Tantry US. The relation of dosing to clopidogrel responsiveness and the incidence of high post-treatment platelet aggregation in patients undergoing coronary stenting. J. Am. Coll. Cardiol. 45(9), 1392–1396 (2005).
  • Angiolillo DJ, Fernández-Ortiz A, Bernardo E et al. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur. Heart J. 25(21), 1903–1910 (2004).
  • Gurbel PA, Tantry US. Drug insight: Clopidogrel nonresponsiveness. Nat. Clin. Pract. Cardiovasc. Med. 3(7), 387–395 (2006).
  • Savi P, Zachayus JL, Delesque-Touchard N et al. The active metabolite of Clopidogrel disrupts P2Y12 receptor oligomers and partitions them out of lipid rafts. Proc. Natl. USA Acad. Sci. 103(29), 11069–11074 (2006).
  • Giusti B, Gori AM, Marcucci R et al. Relation of cytochrome P450 2C19 loss-of-function polymorphism to occurrence of drug-eluting coronary stent thrombosis. Am. J. Cardiol. 103(6), 806–811 (2009).
  • Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med. 360(4), 354–362 (2009).
  • Mega JL, Simon T, Collet JP et al. Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis. JAMA 304(16), 1821–1830 (2010).
  • Giusti B, Gori AM, Marcucci R et al. Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients. Pharmacogenet. Genomics 17(12), 1057–1064 (2007).
  • Marcucci R, Giusti B, Paniccia R et al. High on-treatment platelet reactivity by ADP and increased risk of MACE in good clopidogrel metabolizers. Platelets 23(8), 586–593 (2012).
  • Marcucci R, Gori AM, Paniccia R et al. Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. Atherosclerosis 195(1), e217–e223 (2007).
  • Angiolillo DJ. Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes Care 32(4), 531–540 (2009).
  • Geisler T, Mueller K, Aichele S et al. Impact of inflammatory state and metabolic control on responsiveness to dual antiplatelet therapy in type 2 diabetics after PCI: prognostic relevance of residual platelet aggregability in diabetics undergoing coronary interventions. Clin. Res. Cardiol. 99(11), 743–752 (2010).
  • Simon T, Steg PG, Gilard M et al. Clinical events as a function of proton pump inhibitor use, clopidogrel use, and cytochrome P450 2C19 genotype in a large nationwide cohort of acute myocardial infarction: results from the French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) registry. Circulation 123(5), 474–482 (2011).
  • Cesari F, Marcucci R, Caporale R et al. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb. Haemost. 99(5), 930–935 (2008).
  • Mehta SR, Tanguay JF, Eikelboom JW et al.; CURRENT-OASIS 7 trial investigators. Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. Lancet 376(9748), 1233–1243 (2010).
  • Martin JF, Bath PM, Burr ML. Influence of platelet size on outcome after myocardial infarction. Lancet 338(8780), 1409–1411 (1991).
  • von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation 112(19), 2946–2950 (2005).
  • Montalescot G, Sideris G, Meuleman C et al.; ALBION Trial Investigators. A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J. Am. Coll. Cardiol. 48(5), 931–938 (2006).
  • Patti G, Colonna G, Pasceri V, Pepe LL, Montinaro A, Di Sciascio G. Randomized trial of high loading dose of clopidogrel for reduction of periprocedural myocardial infarction in patients undergoing coronary intervention: results from the ARMYDA-2 (Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty) study. Circulation 111(16), 2099–2106 (2005).
  • Cuisset T, Frere C, Quilici J et al. Benefit of a 600-mg loading dose of clopidogrel on platelet reactivity and clinical outcomes in patients with non -ST-segment elevation acute coronary syndrome undergoing coronary stenting. J. Am. Coll. Cardiol. 48, 1339–1345 (2006).
  • Price MJ, Berger PB, Teirstein PS et al.; GRAVITAS Investigators. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 305(11), 1097–1105 (2011).
  • Collet JP, Cayla G, Cuisset T et al. Randomized comparison of platelet function monitoring to adjust antiplatelet therapy versus standard of care: rationale and design of the assessment with a double randomization of (1) a fixed dose versus a monitoring-guided dose of aspirin and clopidogrel after DES implantation, and (2) treatment interruption versus continuation, 1 year after stenting (ARCTIC) study. Am. Heart J. 161(1), 5–12.e5 (2011).
  • Martin MT, Spinler SA, Nutescu EA. Emerging antiplatelet therapies in percutaneous coronary intervention: a focus on prasugrel. Clin. Ther. 33(4), 425–442 (2011).
  • Farid NA, Smith RL, Gillespie TA et al. The disposition of prasugrel, a novel thienopyridine, in humans. Drug Metab. Dispos. 35(7), 1096–1104 (2007).
  • Varenhorst C, James S, Erlinge D et al. Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease. Eur. Heart J. 30(14), 1744–1752 (2009).
  • Brandt JT, Close SL, Iturria SJ et al. Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel. J. Thromb. Haemost. 5(12), 2429–2436 (2007).
  • Farid NA, Jakubowski JA, Payne CD et al. Effect of rifampin on the pharmacokinetics and pharmacodynamics of prasugrel in healthy male subjects. Curr. Med. Res. Opin. 25(8), 1821–1829 (2009).
  • Small DS, Wrishko RE, Ernest CS 2nd et al. Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease. J. Clin. Pharm. Ther. 34(5), 585–594 (2009).
  • Wallentin L, Varenhorst C, James S et al. Prasugrel achieves greater and faster P2Y12 receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur. Heart J. 29(1), 21–30 (2008).
  • Hall R, Mazer CD. Antiplatelet drugs: a review of their pharmacology and management in the perioperative period. Anesth. Analg. 112(2), 292–318 (2011).
  • Wiviott SD, Trenk D, Frelinger AL et al.; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation 116(25), 2923–2932 (2007).
  • Montalescot G, Sideris G, Cohen R et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb. Haemost. 103(1), 213–223 (2010).
  • Angiolillo DJ, Saucedo JF, Deraad R et al.; SWAP Investigators. Increased platelet inhibition after switching from maintenance clopidogrel to prasugrel in patients with acute coronary syndromes: results of the SWAP (Switching Anti Platelet) study. J. Am. Coll. Cardiol. 56(13), 1017–1023 (2010).
  • Wiviott SD, Antman EM, Winters KJ et al.; JUMBO-TIMI 26 Investigators. Randomized comparison of prasugrel (CS-747, LY640315), a novel thienopyridine P2Y12 antagonist, with clopidogrel in percutaneous coronary intervention: results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)-TIMI 26 trial. Circulation 111(25), 3366–3373 (2005).
  • Bovill EG, Terrin ML, Stump DC et al. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI), Phase II Trial. Ann. Intern. Med. 115(4), 256–265 (1991).
  • Wiviott SD, Braunwald E, McCabe CH et al.; TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 357(20), 2001–2015 (2007).
  • Morrow DA, Wiviott SD, White HD et al. Effect of the novel thienopyridine prasugrel compared with clopidogrel on spontaneous and procedural myocardial infarction in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38: an application of the classification system from the ­universal definition of myocardial infarction. Circulation 119(21), 2758–2764 (2009).
  • Murphy SA, Antman EM, Wiviott SD et al.; TRITON-TIMI 38 Investigators. Reduction in recurrent cardiovascular events with prasugrel compared with clopidogrel in patients with acute coronary syndromes from the TRITON-TIMI 38 trial. Eur. Heart J. 29(20), 2473–2479 (2008).
  • Montalescot G, Wiviott SD, Braunwald E et al.; TRITON-TIMI 38 investigators. Prasugrel compared with clopidogrel in patients undergoing percutaneous coronary intervention for ST-elevation myocardial infarction (TRITON-TIMI 38): double-blind, randomised controlled trial. Lancet 373(9665), 723–731 (2009).
  • Wiviott SD, Braunwald E, Angiolillo DJ et al. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet in-hibition with prasugrel-Thrombolysis in Myocardial Infarction 38. Circulation 118, 1626–1636 (2008).
  • Bhatt DL. Prasugrel in clinical practice. N. Engl. J. Med. 361(10), 940–942 (2009).
  • Deeks ED. Ticagrelor: a review of its use in the management of acute coronary syndromes. Drugs 71(7), 909–933 (2011).
  • Springthorpe B, Bailey A, Barton P et al. From ATP to AZD6140: the d iscovery of an orall y active reversible P2Y12 receptor antagonist for the prevention of thrombosis. Bioorg. Med. Chem. Lett. 17(21), 6013–6018 (2007).
  • VAN Giezen JJ, Nilsson L, Berntsson P et al. Ticagrelor binds to human P2Y(12) independently from ADP but antagonizes ADP-induced receptor signaling and platelet aggregation. J. Thromb. Haemost. 7(9), 1556–1565 (2009).
  • Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur. Heart J. 27(9), 1038–1047 (2006).
  • Teng R, Butler K. Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y(12) receptor antagonist, in healthy subjects. Eur. J. Clin. Pharmacol. 66(5), 487–496 (2010).
  • Gurbel PA, Bliden KP, Butler K et al. Response to ticagrelor in clopidogrel nonrespon ders and responders and effect of switching therapies. The RESPOND study. Circulation 121(10), 1188–1199 (2010).
  • Gurbel PA, Bliden KP, Butler K et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 120(25), 2577–2585 (2009).
  • Cannon CP, Husted S, Harrington RA et al.; DISPERSE-2 Investigators. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome: primary results of the DISPERSE-2 trial. J. Am. Coll. Cardiol. 50(19), 1844–1851 (2007).
  • Wallentin L, Becker RC, Budaj A et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N. Engl. J. Med. 361(11), 1045–1057 (2009).
  • Cannon CP, Harrington RA, James S et al.; PLATelet inhibition and patient Outcomes Investigators. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet 375(9711), 283–293 (2010).
  • Held C, Asenblad N, Bassand JP et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes undergoing coronary artery bypass surgery results from the PLATO (Platelet Inhibition and Patient Outcomes) trial. J. Am. Coll. Cardiol. 57, 672–684 (2011).
  • James S, Angiolillo DJ, Cornel JH et al.; PLATO Study Group. Ticagrelor vs. clopidogrel in patients with acute coronary syndromes and diabetes: a substudy from the Platelet Inhibition and Patient Outcomes (PLATO) trial. Eur. Heart J. 31(24), 3006–3016 (2010).
  • James SK, Storey RF, Khurmi NS et al.; PLATO Study Group. Ticagrelor versus clopidogrel in patients with acute coronary syndromes and a history of stroke or transient ischemic attack. Circulation 125(23), 2914–2921 (2012).
  • Storey RF, Becker RC, Harrington RA et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes [PLATO] pulmonary function substudy). Am. J. Cardiol. 108(11), 1542–1546 (2011).
  • Marcucci R, Gori AM, Paniccia R et al. High on-treatment platelet reactivity by more than one agonist predicts 12-month follow-up cardiovascular death and non-fatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting. Thromb. Haemost. 104(2), 279–286 (2010).

Websites

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.